Edgewise Therapeutics, Inc. EWTX Balance Sheet Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $61.15M+46.8% | $41.67M-51.6% | $86.1M+291% | $21.99M+41.3% | ||
| $543.39M+14.3% | $475.48M+45.4% | $327M-8.4% | $357M+25.8% | ||
| $7.83M-17.6% | $9.5M-9.0% | $10.44M+22.4% | $8.53M+836% | ||
| $552.6M+13.5% | $486.82M+43.2% | $340.04M-7.4% | $367.1M+28.7% | ||
| $29.27M+28.7% | $22.75M+33.8% | $17M-15.1% | $20.03M+89.5% | ||
| $27.37M+14.7% | $23.86M+42.3% | $16.77M+1.1% | $16.59M+57.6% | ||
| $30.35M+9.9% | $27.6M+30.2% | $21.21M+4.0% | $20.39M+87.9% | ||
| $10K+11.1% | $9K+28.6% | $7K+16.7% | $6K+20.0% | ||
| -$546.37M-44.3% | -$378.58M-54.7% | -$244.76M-69.3% | -$144.6M-87.9% | ||
| $522.26M+13.7% | $459.22M+44.0% | $318.83M-8.0% | $346.72M+26.4% | ||
| $552.6M+13.5% | $486.82M+43.2% | $340.04M-7.4% | $367.1M+28.7% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Can Edgewise Therapeutics, Inc. cover its short-term obligations?
- Its current ratio is 22.61 — current assets exceed current liabilities.
- Where does Edgewise Therapeutics, Inc.'s balance sheet data come from?
- Every line is extracted from Edgewise Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.